PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (EP3066108) 4-{4-[(1E)-4-(2,9-DIAZASPIRO[5.5]UNDEC-2-YL)BUT-1-EN-1-YL]-2-METHYLBENZYL}-5-(PROPAN-2-YL)-1H-PYRAZOL-3-YL BETA-D- GLUCOPYRANOSIDE ACETATE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters
Claims

1. A compound of the formula:

or hydrate thereof.
  2. A crystalline form of the compound according to claim 1 which is hydrated.
  3. The compound according to claim 2 characterized by at least one of the following:

a. an X-ray powder diffraction pattern using CuKα radiation having an intense peak at diffraction angle 2-theta of 5.2° in combination with one or more intense peaks selected from the group consisting of 7.8°, 8.0°, and 10.7° (± 0.2° respectively); and

b. a 13C solid state NMR spectrum which comprises peaks referenced to the highfield resonance of adamantane (δ=29.5 ppm) at: 181.8, 161.2, 160.0, 147.6 and 137.4 ppm (±0.2 ppm respectively);

wherein the term intense peak means a peak having an intensity that is at least 5% that of the most intense peak in the relevant spectrum or powder pattern.
  4. The compound according to any of claims 1 to 3 wherein the water content at ambient temperature is in the range of 9% to 12% by weight.
  5. A compound according to any one of claims 1 to 4 for use in therapy.
  6. A compound according to any one of claims 1 to 4 for use in the treatment of diabetes.
  7. A compound for use according to claim 6 wherein the diabetes is type 1 diabetes.
  8. A compound for use according to claim 6 wherein the diabetes is type 2 diabetes.
  9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 with one or more pharmaceutically acceptable carriers, diluents, or excipients.